

## **Algorae Pharmaceuticals Limited – Half Yearly Report Ended 31 December 2023**

Melbourne, Australia, 28 February 2024: Algorae Pharmaceuticals Limited (Algorae or the Company) (ASX code: 1AI) announces the half yearly report for the six months ended 31 December 2023. The report is enclosed.

Algorae is a pharmaceutical development company with three drug candidates and a proprietary artificial intelligence (AI) biopharmaceutical prediction platform under development. Algorae's therapeutic pipeline comprises AI-116 for dementia, AI-168 for cardiovascular disease and NTCELL for Parkinson's disease. The Company's AI biopharmaceutical prediction platform, called Algorae Operating System (AlgoraeOS), is being developed by AI experts at the University of NSW. It is designed to predict synergistic combination drug targets using machine learning, deep learning, and neural network algorithms over a multitude of extensive and multi-disciplinary public and private scientific and medical databases. Promising AI generated drug targets will be added to the Company's therapeutic pipeline or licensed to third parties.

**This announcement has been approved by the Board of Directors of Algorae Pharmaceuticals Limited.**

**End**

For more information, please visit [www.algoraepharma.com](http://www.algoraepharma.com)

### **Corporate and Media Enquiries**

Mr Brad Dilkes - Director

P: +61 422 180 317

E: [brad@algoraepharma.com](mailto:brad@algoraepharma.com)

### **Forward-looking Statements**

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

# Appendix 4D

## Half year report for the six months ended 31 December 2023

<b>Name of Entity</b>	Algorae Pharmaceuticals Limited
<b>ACN</b>	104 028 042
<b>Financial Period Ended</b>	31 DECEMBER 2023
<b>Previous Corresponding Reporting Period</b>	31 DECEMBER 2022

	<b>\$ 31 Dec 2023</b>	<b>\$ 31 Dec 2022</b>	<b>\$ Change</b>	<b>Percentage increase /(decrease) over the previous corresponding</b>
<b>Revenue from ordinary activities</b>	50,581	8,494	42,087	495.49 %
<b>Profit / (loss) from ordinary activities after tax attributable to members</b>	(1,451,090)	(1,306,520)	(144,570)	11.07 %
<b>Net profit / (loss) for the period attributable to members</b>	(1,451,090)	(1,306,520)	(144,570)	11.07 %

<b>Dividends (distributions)</b>	<b>Amount per security</b>	<b>Franked amount per security</b>
<b>Final Dividend</b>	Nil	Nil
<b>Previous corresponding period</b>	Nil	Nil
<b>Interim Dividend</b>	Nil	Nil
<b>Previous corresponding period</b>	Nil	Nil

<b>The record date for determining entitlements to the dividends (if any)</b>	<b>NA</b>
-----------------------------------------------------------------------------------	-----------

**A brief explanation of any of the figures reported above necessary to enable the figures to be understood:**

Refer to Consolidated Interim Financial Report.

**The half-yearly report is to be read in conjunction with the most recent annual financial report.**

**NTA Backing**

	<b>Current period</b>	<b>Previous corresponding period Cents</b>
<b>Net tangible assets backing per ordinary security</b>	0.21 cents per share	0.24 cents per share

**Control Gained Over Entities Having Material Effect**

<b>Name of entity (or group of entities)</b>	N/A
<b>Date control gained</b>	
<b>Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired</b>	
<b>Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period</b>	

**Loss of Control Gained Over Entities Having Material Effect**

<b>Name of entity (or group of entities)</b>	N/A
<b>Date control gained</b>	
<b>Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired</b>	
<b>Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period</b>	

**Details of Associates and Joint Venture Entities**


<b>Name of Entity</b>	<b>Percentage Held</b>		<b>Share of Net Profit</b>	
	<b>Current period</b>	<b>Previous period</b>	<b>Current period</b>	<b>Previous Period</b>
<b>Aggregate Share of Net Profits</b>			\$nil	\$nil

**Audit / Review Status**

<b>This report is based on accounts to which one of the following applies:</b> (Tick one)			
The accounts have been audited	<input type="checkbox"/>	The accounts have been subject to review	<input checked="" type="checkbox"/>
The accounts are in the process of being audited or subject to review	<input type="checkbox"/>	The accounts have not yet been audited or reviewed	<input type="checkbox"/>
<b>If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:</b>  Not Applicable			
<b>If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification:</b>  Not Applicable			

**Attachments Forming Part of Appendix 4D**

<b>Attachment #</b>	<b>Details</b>
1	ASX Announcement
2	Consolidated Interim Financial Report for the 6 months to 31 December 2023

<b>Signed By (Company Secretary)</b>	
<b>Print Name</b>	David Hainsworth
<b>Date</b>	28 February 2024